CLOSED
Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company also offers its products for various therapeutic categories, such as anti- diabetic, anti-malarial, anti-infectives, anti-neoplastic, blood related, cardiac, gastro-intestinal, g. Track Gland Pharma Limited's live NSE:GLAND share price ₹2,574.40 (+2.78%), market cap ₹₹425B, P/E 41.3. MarketRipple's AI analysis covers the investment thesis, ripple-chain impact, and Healthcare sector outlook for GLAND — real-time NSE India stock intelligence.
Open
₹2,505.60
High
₹2,582.00
Low
₹2,494.10
Prev. Close
₹2,504.80
52W High
₹2,586.00
52W Low
₹1,573.60
Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company also offers its products for various therapeutic categories, such as anti- diabetic, anti-malarial, anti-infectives, anti-neoplastic, blood related, cardiac, gastro-intestinal, g
Key Takeaway
Gland Pharma Limited is rated buy with a P/E of 41.3x — understand the valuation context before sizing a position.
★ Recommended
Ask AI: Is Gland Pharma Limited fairly valued right now?
Because a P/E of 41.3x needs to be compared against sector peers and growth expectations to be meaningful.
Continue Research
View events affecting Gland Pharma Limited
Because the investment case must account for macro and company-specific developments — events reveal the 'why' behind price moves.
Trace sector ripple effects
Because Healthcare moves create upstream and downstream implications that affect the entire thesis.
Intelligence Path
Growth
Govt Exposure
Policy Dependence
Execution Quality
News Sensitivity
Debt Strength
1,743 Cr
Revenue
367 Cr
Net Profit
10.5%
ROE
0%
ROCE
62.32
EPS
| ₹ in Crore | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|
| Revenue | 3,592 | 5,642 | 5,617 | 6,431 | 6,369 |
| Net Profit | 781 | 772 | 699 | 1,027 | 1,030 |
| ROE (%) | — | — | — | 10.5% | 10.5% |
| EPS (₹) | — | — | — | 62.32 | 62.32 |
| Debt/Equity | — | — | — | 2.7 | 2.7 |